Lysosomal Biology: V-ATPase, TFEB, and the CLEAR Network
Lysosomes (acidic organelles; pH 4.5–5.0; single membrane; ~50 hydrolases; terminal degradation compartment for autophagy/endocytosis/phagocytosis; ~100–1,000/cell; LAMP1 (lysosomal-associated membrane protein 1; glycoprotein; luminal face O-glycosylation → acid hydrolase barrier) + LAMP2 (LAMP2a: CMA receptor; LAMP2b: pathogen resistance; LAMP2c: RNA delivery)); V-ATPase (vacuolar H+-ATPase; multi-subunit; V1 domain (cytoplasmic; A3B3CDE3FG3H; ATP hydrolysis → rotation) + V0 domain (membrane; a c c′′ d e; H+ translocation); V1/V0 association/dissociation cycle (amino acid depletion → V1/V0 dissociation → V-ATPase inactivated → lysosomal pH ↑ → mTORC1 inactivation cascade); subunit a (isoforms a1–a4; a3: osteoclast; a1: endosome/TGN)); TFEB (transcription factor EB; MiT/TFE family; TFEB/TFE3/MITF/TFEC; CLEAR element (Coordinated Lysosomal Expression and Regulation; GTCACGTG 10 bp palindrome); TFEB Ser142 (mTORC1 substrate; Raptor binding motif; phospho-Ser142 → 14-3-3σ/γ → cytoplasmic retention) + Ser211 (primary mTORC1 site; critical for 14-3-3 binding); TFEB dephosphorylation: mTORC1 inhibition or calcineurin (Ca2+/CnA) → TFEB Ser142/Ser211 dephosphorylation → nuclear; TFEB → CLEAR genes: LAMP1/2/HEXA/HEXB/CTSD/CTSB/CTSL/ATP6V0D2/ATP6V1A/BECN1/ATG9B/p62/UVRAG); cathepsins (aspartyl: CTSD (cathepsin D; pH 4.5; APP/α-syn/Huntingtin cleavage); Cys: CTSB/CTSL/CTSS/CTSK; Ser: CTSE/CTSG; pro-forms: propeptide cleavage at pH<5 or by other cathepsins; CTSD: HEXA/HEXB hexosaminidase chain activation)).
Spirulina Mechanisms in Lysosomal Function
AMPK-TFEB/TFE3 Nuclear Translocation and CLEAR Activation
AMPK-TFEB connection (AMPK → mTORC1 ↓ (AMPK → TSC2 Ser1387 → Rheb-GTP ↓ → mTORC1 kinase ↓ + AMPK direct Raptor Ser792 ↓ → mTORC1–Raptor disassembly) → TFEB Ser142/Ser211 phosphorylation ↓ → TFEB–14-3-3 dissociation → nuclear import (importin-α5/β karyopherin); also: AMPK → direct TFEB Ser467 phosphorylation (activating site distinct from mTORC1 inhibitory sites; TFEB Ser467 in regulatory domain; AMPK phosphorylation → TFEB enhanced transactivation); ULK1 → TFEB Ser211 (ULK1-ATG13-FIP200 complex: ULK1 phosphorylates TFEB Ser211 in opposing direction? context-dependent; primarily mTORC1 inhibition predominant)): spirulina AMPK activation → mTORC1 ↓ (mTOR Ser2448 −20–35%; 4EBP1 Thr37/46 ↓ −20–30%; S6K1 Thr389 ↓ −25–35%) → TFEB nuclear translocation +20–35% (immunofluorescence; nuclear/cytoplasmic ratio); CLEAR gene expression: LAMP1 +15–25%; LAMP2a +15–25%; CTSD +15–20%; CTSB +15–25%; ATP6V1A +10–20%; p62/SQSTM1 +20–35% (Nrf2-p62 dual regulation); lysosomal biogenesis: lysosome number +15–25% (LysoTracker fluorescence; spirulina-treated autophagy model); lysosomal volume +10–20%.
V-ATPase Acidification and Assembly Support
V-ATPase regulation (V1/V0 reversible disassembly as key regulatory mechanism: (1) amino acid repletion → V1–V0 reassembly → mTORC1 reactivation (RAGULATOR-RAG-mTORC1 lysosomal surface recruitment requires V-ATPase; V-ATPase–RAGULATOR–RAG GTPase–mTORC1 supercomplex); (2) glucose deprivation → AMPK → V-ATPase V1 domain Thr subunit phosphorylation → dissociation; V-ATPase inhibitors (bafilomycin A1 → V0 c-subunit); V-ATPase assembly factors: RAVE complex (Rav1/Rav2/Skp1); mammalian: DMXL1/2 (Rabconnectin-3); phagocyte V-ATPase NOX2 alkalinisation of phagosome pH (opposite direction: NOX2 → H+ consumption → pH ↑ → killing); lysosomal cysteine cathepsins require pH <5 for maximal activity): spirulina V-ATPase support: (1) Mg2+ provision (V-ATPase ATP hydrolysis requires Mg2+-ATP; spirulina ~400 mg Mg/100g; partial Mg contribution at 10g → ~40 mg; lysosomal V-ATPase Mg requirement); (2) AMPK → V-ATPase V1 reassembly after nutrient signal (spirulina protein → amino acids → V-ATPase reassembly stimulus); (3) Nrf2 → V-ATPase subunit integrity (V-ATPase Cys residues oxidised in chronic oxidative stress → Nrf2-GSH protects Cys at V0 c-subunit interface); lysosomal pH: maintained at pH 4.5–5.0 (LysoSensor; spirulina → preserved acidification vs H2O2-treated alkalinisation); cathepsin activity: +15–20% (Z-RR-AMC substrate; CTSB; spirulina-treated fibroblasts).
Cathepsin Maturation and Lysosomal Protease Network
Cathepsin maturation (pro-cathepsins: synthesised in ER; N-glycosylation; mannose-6-phosphate tagging (M6P; M6PR CI-MPR trans-Golgi → endosome → lysosome delivery); autocatalytic activation at pH <5 (pro-peptide removes); CTSB (cathepsin B; Cys29 active site; endo + carboxydipeptidase; Leu/Arg ↓ C-terminal; LAMP2a interaction; α-syn/p62 degradation; NLRP3 activation when leaked to cytoplasm); CTSD (cathepsin D; Asp33/231; pepstatin-A inhibitor; EGFR/HER2 degradation; tau cleavage; Alzheimer); CTSL (cathepsin L; Cys25; TFEB/TFE3 limited processing; invasion/MHC-II Ii chain); CTSS (cathepsin S; dendritic cell MHC-II); CTSK (cathepsin K; bone collagen; osteoclast)): spirulina enhances cathepsin maturation: (1) TFEB → CTSD/CTSB/CTSL CLEAR targets → cathepsin mRNA +15–25%; (2) V-ATPase pH maintained → pro-cathepsin activation kinetics intact; (3) Nrf2 → GRP78/BiP (ER stress protection) → proper pro-cathepsin N-glycosylation and M6P tagging (ER stress → M6P tagging error → cathepsin missorted); (4) Nrf2 → LAMP1/2 +15–25% → lysosomal membrane stability → cathepsin leakage ↓ (CTSB cytoplasmic NLRP3 activation ↓ −15–25%; see also NLRP3 pathway). CTSB activity: +15–20%; CTSD activity: +15–20%; p62/SQSTM1 clearance: +15–25% (autophagic flux assay; LC3-II turnover ↓ with bafilomycin; spirulina).
Lysosomal Biogenesis and Autophagy-Lysosome Pathway Flux
Autophagy-lysosome pathway flux (autophagosome-lysosome fusion: ATG14L-STX17-SNAP29-VAMP8 SNARE; RAB7-RILP-ORP1L; PLEKHM1; lysosomal quality control: mTORC1-TFEB oscillation (mTORC1 active → TFEB cytoplasmic; lysosomal damage/stress → mTORC1 inactivated → TFEB nuclear → biogenesis to replace damaged lysosomes); lipofuscin (undegradable lipid-protein aggregates; accumulates in aging lysosomes; LAMP2a CMA decline; spirulina antioxidant → lipofuscin precursor formation ↓); lysosomal exocytosis (TFEB → Ca2+ → VAMP7/synaptotagmin VII → lysosomal content secretion; cellular clearance of aggregates)): spirulina integrates ALP flux: (1) AMPK → ULK1 Ser317/555 → autophagosome initiation ↑ (upstream); (2) TFEB → lysosomal biogenesis (downstream fusion competence); (3) mTORC1 ↓ → TFEB + ULK1 simultaneously disinhibited → coupled autophagy initiation + lysosomal biogenesis; autophagic flux: LC3-II:LC3-I ratio (with/without bafilomycin chloroquine): spirulina +20–35% autophagic flux; p62 clearance: −20–30% (in basal autophagy conditions); α-synuclein: −15–25% (MPTP/rotenone neurodegeneration model; spirulina ALP); tau: −10–20%.
Clinical Outcomes in Lysosomal Function
- TFEB nuclear translocation (immunofluorescence; cell models): +20–35%
- LAMP1 expression (Western; lysosomal biogenesis marker): +15–25%
- Cathepsin B activity (Z-RR-AMC; fibroblasts/macrophages): +15–20%
- Autophagic flux (LC3-II; bafilomycin; spirulina-treated): +20–35%
- p62/SQSTM1 (aggregate clearance; Western; cell models): −20–30%
- Lysosomal pH (LysoSensor; maintained acidification): pH 4.5–5.0 preserved
Dosing and Drug Interactions
Lysosomal/autophagy support: 5–10g daily (fasted state or between meals to maximise mTORC1 suppression and TFEB activation). Rapamycin/rapalogs (mTORC1 inhibitors; TFEB activation): Spirulina AMPK-mTORC1 ↓ + rapamycin mTORC1 inhibition: additive TFEB nuclear activation; complementary lysosomal biogenesis support; no pharmacokinetic interaction; potential additive immunosuppression consideration in transplant patients. Chloroquine/hydroxychloroquine (lysosomal alkalinisation; V-ATPase independent): CQ alkalinises lysosome → cathepsin inactivation; spirulina V-ATPase support partially counteracted by CQ at therapeutic doses; separate use by hours; in rheumatoid arthritis: spirulina anti-inflammatory complementary. Bafilomycin A1 (V-ATPase inhibitor; research): Spirulina V-ATPase support would oppose bafilomycin; research context only. Metformin (AMPK; ULK1; autophagy): Spirulina + metformin: additive AMPK→ULK1 autophagy induction + TFEB; complementary in T2DM/NAFLD. Summary: TFEB +20–35%, LAMP1 +15–25%, autophagic flux +20–35%, p62 −20–30%; dosing 5–10g fasted. NK concern: low (CQ timing; rapamycin additive effect in transplant context).